Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
NCT04155580 · Astex Pharmaceuticals, Inc. · PHASE1 · terminated · last registry update 2024-08-02 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention” | Open Targets' class: uncategorised | Registry record, Astex Pharmaceuticals, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DNMT3A in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-05-30Also stopped (withdrawn): Institute of Hematology & Blood Diseases Hospital, China, Decitabine (NCT03021395)
- 2025-05-25Also stopped (withdrawn): City of Hope Medical Center, Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001 + Cyclophosphamide (NCT06572631)
- 2025-05-15Phase 3 first posted: Ruijin Hospital, Decitabine + Sorafenib (BAY-43-9006)，giritinib (NCT06972641)
- 2025-04-22Also stopped (withdrawn): University of Florida, Cladribine + Cytarabine (NCT05766514)
- 2025-03-24Also stopped (withdrawn): Columbia University, Thioguanine (Tabloid ®) + DecitabineCedazuridine (Inqovi ®) (NCT06351306)
- 2025-03-12Also stopped (withdrawn): M.D. Anderson Cancer Center, ASTX727 + ASTX029-01 (NCT06113289)
- 2025-01-07Results posted on the registry: National Cancer Institute (NCI), Decitabine + Ipilimumab (NCT02890329)
- 2024-12-19Results posted on the registry: BerGenBio ASA, Bemcentinib + Cytarabine (NCT02488408)
- 2024-12-03Phase 3 first posted: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, High intensity therapies + Low intensity therapies (NCT06713837)
- 2024-10-22Results posted on the registry: National Cancer Institute (NCI), Decitabine + Nivolumab (NCT04277442)
- 2024-07-23Results posted on the registry: National Cancer Institute (NCI), Azacitidine + Cytarabine (NCT03092674)
- 2024-07-01Results posted on the registry: Astex Pharmaceuticals, Inc., ASTX727 + Dacogen (NCT03306264)
- 2024-06-14Also stopped (withdrawn): Northside Hospital, Inc., Venetoclax + Decitabine (NCT06337331)
- 2024-03-29Also stopped (terminated): Technische Universität Dresden, Eltrombopag + Placebo (NCT02446145)
- 2024-03-22Also stopped (terminated): Kartos Therapeutics, Inc., KRT-232 + Cytarabine (NCT04113616)
- 2024-03-07Phase 3 first posted: Ruijin Hospital, Decitabine + Fludarabine Injection (NCT06297772)
- 2024-02-29Phase 3 first posted: The Second Affiliated Hospital of Kunming Medical University, a drug against DNMT3A (NCT06285136)
- 2023-11-07Results posted on the registry: Masonic Cancer Center, University of Minnesota, Decitabine + Ruxolitinib (NCT04055844)
- 2023-10-23Also stopped (suspended): Innovent Biologics (Suzhou) Co. Ltd., IBI188 + Azacitidine (NCT04485052)
- 2023-10-10Phase 3 first posted: The Second Affiliated Hospital of Kunming Medical University, a drug against DNMT3A (NCT06073730)
- 2023-10-03Also stopped (withdrawn): Racura Oncology Ltd, Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) (NCT05456269)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision